Vanda Pharmaceuticals Inc. (VNDA)

In August 2025, a D.C. Circuit ruling favored Vanda regarding HETLIOZ for jet lag disorder. In October 2025, Vanda reported an 18% year-over-year increase in total net product sales and announced a collaborative framework agreement with the FDA. In November 2025, VNDA's stock rallied in anticipation of the FDA decision on tradipitant for motion sickness, and the FDA lifted a partial clinical hold on Tradipitant. In December 2025, the FDA approved NEREUS for the prevention of motion sickness. In January 2026, Vanda Pharmaceuticals' stock fell after the FDA rejected its supplemental New Drug Application for HETLIOZ to treat jet lag disorder.

Demand seasonality appears to be a factor for Vanda Pharmaceuticals' newly approved motion sickness drug, NEREUS, with the company aiming to capitalize on 2026 travel season demand. There is no clear indication of significant seasonal demand patterns for HETLIOZ, Fanapt and PONVORY.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with high unmet medical needs, particularly for central nervous system disorders. Its commercial portfolio includes HETLIOZ for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances in Smith-Magenis Syndrome, Fanapt for schizophrenia and bipolar I disorder, PONVORY for relapsing forms of multiple sclerosis, and NEREUS for the prevention of motion sickness. The company also has a pipeline of other products in development.

Vanda Pharmaceuticals primarily sells its products in the United States, with a market presence also in Israel, Europe, and Canada. The company is headquartered in Washington D.C., United States, and maintains offices in the United Kingdom and Germany.

Vanda Pharmaceuticals' brand reputation has been influenced by both positive and negative regulatory outcomes in the past year. The FDA approval of NEREUS enhanced the company's reputation as an innovator. Conversely, the FDA's rejection of the HETLIOZ sNDA for jet lag disorder could negatively impact the company's reputation.

Vanda Pharmaceuticals Inc. has a mixed ownership structure, with approximately 75.99% of the stock held by institutional shareholders, including BlackRock Inc. and Vanguard Group Inc. James E. Flynn is the largest individual shareholder, owning 14.67% of the company. Insiders hold about 68.91% of the company's stock.